CD70 patent in the US
Immunicum today announced that the United States Patent and Trademark Office (USPTO) intends to grant a patent relating to the Company’s CD70-technology.
– This further improves our already strong IP portfolio. The decision from the United States Patent and Trademark Office, USPTO, gives us important protection for our CD70-technology, says Jamal El-Mosleh, CEO of Immunicum.
The US patent to be granted, with the title “Method for proliferation of antigen-specific T cells”, protects the method for expansion of tumor specific T cells for so called adoptive immunotherapy with CAR T cells.